Table 1.
Summary of prior large-randomized trials of different GEP-NET treatments
| Trial/Agents | Tumor type | No. of patients | Response rate (%) | Progression-free survival (mo) | Hazard ratio (95% CI) |
|---|---|---|---|---|---|
| PROMIDa) [9] | Midgut NET | ||||
| Octreotide | 42 | - | 14.3 | 0.34 (0.20–0.59) | |
| Placebo | 43 | - | 6.0 | ||
| CLARINET [10] | GEP-NETs | ||||
| Lanreotide | 101 | - | Not reached | 0.47 (0.30–0.73) | |
| Placebo | 103 | - | 18.0 | ||
| RADIANT-3 [11] | Pancreatic NET | ||||
| Everolimus | 204 | 5 | 11.0 | 0.35 (0.27–0.45) | |
| Placebo | 203 | 2 | 4.6 | ||
| RADIANT-4 [12] | Lung and GI NETs | ||||
| Everolimus | 205 | 2 | 11.0 | 0.48 (0.35–0.67) | |
| Placebo | 97 | 1 | 3.9 | ||
| Raymond et al. [13] | Pancreatic NET | ||||
| Sunitinib | 86 | 9.3 | 11.4 | 0.42 (0.26–0.66) | |
| Placebo | 85 | 0 | 5.5 | ||
| NETTER-1 [14] | Midgut NET | ||||
| 177Lu-DOTATATE | 116 | 18 | Not reached | 0.21 (0.13–0.33) | |
| High-dose octreotide | 113 | 3 | 8.4 | ||
| Kunz et al. [15] | Pancreatic NET | ||||
| CAPTEM | 72 | 33.3 | 22.7 | 0.58 (0.36–0.93) | |
| Temozolomide | 72 | 27.8 | 14.4 |
CAPTEM, capecitabine plus temozolomide; CI, confidence interval; GEP, gastroenteropancreatic; GI, gastrointestinal; NET, neuroendocrine tumor.
a)
TTP (time to progression) was used instead of progression-free survival in this trial.